Table 2. Scheme of the DESKTOP-3 and GOG-213 trials.

Variables	DESKTOP-3	GOG-213
Design	Randomized phase 3 trial	Randomized phase 3, 1:1 trial
Primary endpoint	Overall survival	Overall survival
Enrolled patients (study period)	408 women (2010–2015)	485 women (2007–2017)
Patient selection	Treatment-free interval >6 months, AGO score	Treatment-free interval >6 months
Race/ethnicity	2% East-Asian	49.5% East-Asian
Complete resection	72.5%	67%
Bevacizumab in 2nd-line	20%	84%
HR for death (surgery vs. no surgery)	Still blinded	1.29 (95% CI=0.97–1.72; p=0.08)

AGO, Arbeitsgemeinschaft Gynaekologische Onkologie; CI, confidence interval; HR, hazard ratio; GOG, Gynecologic Oncology Group.